Nanoviricides (NNVC) Cash from Operations (2010 - 2026)
Nanoviricides (NNVC) posted Cash from Operations of 1974094.0 for Q1 2026, up 1.3% sequentially from 2000000.0 in Q4 2025, and up 0.85% YoY from 1957506.52 in Q1 2025.
Nanoviricides (NNVC) Cash from Operations (2010 - 2026) Analysis & Trends
Nanoviricides has reported Cash from Operations for 17 years, with the latest figure at 1974094.0 in Q1 2026.
- Quarterly Cash from Operations rose 0.85% year-over-year to 1974094.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7276000.0 (up 11.89% YoY) and the FY2025 annual result came in at 8478679.0, down 34.25% from the prior year.
- Cash from Operations climbed to 1974094.0 in Q1 2026 per NNVC's latest filing, from 2000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1032858.0 in Q3 2022 and troughed at 2594863.0 in Q3 2024.
- A 5-year average of 1711245.71 and a median of 1701906.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations sank 121.46% in 2024, then jumped 38.34% in 2025.
- Over 5 years, Cash from Operations stood at 1400522.0 in 2022, then slipped by 22.74% to 1718975.0 in 2023, then declined by 27.46% to 2190945.0 in 2024, then grew by 8.72% to 2000000.0 in 2025, then advanced by 1.3% to 1974094.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 1974094.0, 2000000.0, and 1600000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 728.46 Mn |
| 10 | Nanoviricides | 29.06 Mn | 25.85 Mn | - | -1.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.97 Mn |
| Mar 31, 2026 | -1.97 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.19 Mn |
| Dec 31, 2024 | -2.19 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Jun 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.48 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Mar 31, 2024 | -1.94 Mn |
| Dec 31, 2023 | -1.72 Mn |
| Dec 31, 2023 | -1.72 Mn |